Correction: Integrating network pharmacology, molecular docking and experimental verification to explore the therapeutic effect and potential mechanism of nomilin against triple-negative breast cancer
Zhixuan Wu, Haoyi Xiang, Xiaowu Wang, Rongrong Zhang, Yangyang Guo, Liangchen Qu, Jingyao Zhou, Yanyi Xiao
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMicrobial Natural Products and Biosynthesis · Computational Drug Discovery Methods
Molecular Medicine (2024) 30:166
10.1186/s10020-024-00928-2
In this article (Wu et al. 2024) the affiliation details for the author Zhixuan Wu were incorrectly given as ‘The Dingli Clinical College of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China’ and ‘Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China’ but should have been ‘Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang Province 325035, China.’
The original article has been corrected.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Wu, Z., Xiang, H., Wang, X. et al. Integrating network pharmacology, molecular docking and experimental verification to explore the therapeutic effect and potential mechanism of nomilin against triple-negative breast cancer. Mol Med 30, 166 (2024). 10.1186/s 10020-024-00928-210.1186/s 10020-024-00928-2PMC 1143931839342122 · doi ↗ · pubmed ↗